A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

This study tests a new investigational tablet called HRS-5041 in men with advanced prostate cancer. It is being combined with other anti-cancer therapies to see if it is safe and effective for treating prostate cancer that has continued to grow despite standard treatments. **You may be eligible if:** - You are a man aged 18 to 80 years (or any age above 18 in later phases) - You have histologically confirmed prostate adenocarcinoma (a specific type of prostate cancer) - You have good general health (ECOG score 0 or 1) and expected survival of at least 12 weeks - Your organ function is adequate for trial participation - Your partner uses reliable contraception if she can become pregnant **You may NOT be eligible if:** - You are currently receiving or planning to receive another anti-cancer treatment during this study - You have neuroendocrine or small cell prostate cancer (a more aggressive subtype) - Your general health is too poor to tolerate study treatment Talk to your doctor to see if this trial is right for you.